Case report of acute kidney injury following accelerated tirzepatide dosing in a patient with multiple comorbidities highlights the importance of gradual dose titration.
Key findingCase report of acute kidney injury following accelerated tirzepatide dosing in a patient with multip
What the researchers found
Case report of acute kidney injury following accelerated tirzepatide dosing in a patient with multiple comorbidities highlights the importance of gradual dose titration.
Why it matters
Relevant to expanding peptide-based therapeutic applications.
The numbers in context
Single patient case with multiple comorbidities. AKI developed after dose escalation faster than the recommended schedule.
How the study worked
Methodology detailed in publication.
Who was studied
Single patient with multiple comorbidities who received accelerated tirzepatide dosing
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
Contributes to the growing evidence for peptide therapeutics.
Questions still open
- Long-term implications?
- Comparison to existing evidence?
- Next research steps?
Common questions
What does this mean?
How reliable?
Read the original research
Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.
The American journal of case reports, 26, e950781
Citation
Almansour, Abdulelah H. (2025). Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.. The American journal of case reports, 26, e950781. https://doi.org/10.12659/AJCR.950781